Ipamorelin
Growth hormone axis · By Preptide Pro editorial team · Last updated
Ipamorelin is a growth hormone axis peptide, and it is not FDA-approved. A synthetic ghrelin-receptor agonist (growth hormone secretagogue). Studied in animals and in early human trials for postoperative gut recovery.
Not FDA-approvedChemistry (PubChem)
| PubChem CID | 9831659 |
|---|---|
| CAS number | 170851-70-4 |
| Molecular formula | C38H49N9O5 |
| Molecular weight | 711.9 g/mol |
| Other names | Ipamorelin, NNC-26-0161, Aib-His-D-2-Nal-D-Phe-Lys-NH2, NNC-260161, NNC 26-0161, Aib-His-2Nal-Phe-Lys-NH2, RefChem:148620, DTXCID9091446 |
Is Ipamorelin FDA-approved?
Not FDA-approved. No matching NDA or BLA was found in openFDA (Drugs@FDA).
How much research is there on Ipamorelin?
PubMed lists 55 records for “ipamorelin”, of which 2 are tagged as human clinical trials.
| Recent study | Journal | Date |
|---|---|---|
| Peptides in urology and sexual medicine: clinical effectiveness, dosing, indications, and safety: a narrative review. | Sex Med Rev | 2026 Sep 30 |
| Peptide Supplements and Their Therapeutic Applications in Sports Medicine. | Am J Sports Med | 2026 Aug 11 |
| Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. | Sports Med | 2026 Aug |
| A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. | J Sports Med Phys Fitness | 2026 Jul |
| The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. | Front Endocrinol (Lausanne) | 2026 |
Sources
This is general research information, not medical advice. Check with a clinician before using any compound.